tirzepatide cardiovascular outcomes trial SURPASS-CVOT Published: Large Confirms CVD Efficacy of Tirzepatide Matches Dulaglutide in Large

While a nasal spray variation of Bremelanotide exists and was tested in clinical trials, intranasal administration is discouraged because of its higher incidence of adverse effects in some trials

no published human pharmacokinetic data confirms what fraction of a nasal spray dose reaches the bloodstream

doi: 10.1186/s40959-021-00095-x 260 CautelaJZeriouhSGaubertMBonelloLLaineMPeyrolMet al

The underlying pharmacological rationale for this specific tripartite combination relies on targeting multiple physiological bottlenecks simultaneously, thereby preventing the biological healing process from stalling at any single point of failure

doi: 10.1080/00926230902851322